LOGIN  |  REGISTER
Cue Biopharma

AtriCure (NASDAQ: ATRC) Stock Quote

Last Trade: US$22.76 -1.00 -4.21
Volume: 461,560
5-Day Change: 3.17%
YTD Change: -36.21%
Market Cap: US$1.100B

Latest News From AtriCure

MASON, Ohio / May 15, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure’s management is scheduled to participate in a fireside... Read More
Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio / May 01, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by... Read More
MASON, Ohio / Apr 30, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securities Healthcare Conference. AtriCure’s management is scheduled to present on Tuesday, May 14,... Read More
MASON, Ohio / Apr 18, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE ® + cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE ®... Read More
MASON, Ohio / Apr 10, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1,... Read More
MASON, Ohio / Mar 26, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. AtriCure’s management is scheduled to participate in a fireside... Read More
Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year Full Year 2023 International revenue of $65.7 million – an increase of 23.5% year over year Full Year 2023 Net loss of $30.4 million – an improvement of $16.0... Read More
MASON, Ohio / Jan 25, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time... Read More
MASON, Ohio / Jan 08, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2023 and provided 2024 financial guidance. Preliminary, unaudited revenue for fourth quarter 2023 is expected... Read More
MASON, Ohio / Jan 04, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman’s long and distinguished career in the medical device industry has placed him at the forefront of new... Read More
MASON, Ohio / Dec 20, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, January 10, 2024, at... Read More
MASON, Ohio / Nov 15, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35 th Annual Healthcare Conference. AtriCure’s management is scheduled to participate in a fireside chat on... Read More
MASON, Ohio / Nov 14, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company’s corporate responsibility and sustainability... Read More
Worldwide revenue of $98.3 million – an increase of 18.1% year over year U.S. revenue of $81.7 million – an increase of 17.1% year over year International revenue of $16.6 million – an increase of 23.2% year over year Net loss of $9.1 million – an improvement of $3.2 million year over year Positive adjusted EBITDA of $4.7 million – an improvement of $5.4 million year over year MASON, Ohio / Nov 01, 2023 / Business Wire /... Read More
MASON, Ohio / Oct 31, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2023 Healthcare Conference. AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, November 14,... Read More
MASON, Ohio / Oct 11, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday,... Read More
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvement of $9.7 million year over year Positive adjusted EBITDA of $8.0 million – an improvement of $11.2 million year over year MASON, Ohio / Jul 25, 2023 / Business Wire /... Read More
MASON, Ohio / Jul 21, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure will be participating in the Canaccord Genuity 43 rd Annual Growth Conference.... Read More
MASON, Ohio / Jul 03, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 25, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, July 25,... Read More
Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improvement of $8.7 million year over year Positive adjusted EBITDA of $1.9 million – an improvement of $6.2 million year over year MASON, Ohio / May 02, 2023 / Business Wire /... Read More
MASON, Ohio / Apr 19, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an investor education webcast in conjunction with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. The company also announced that... Read More
MASON, Ohio / Apr 11, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 2, 2023,... Read More
MASON, Ohio / Apr 03, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference. AtriCure’s management is scheduled to participate in a fireside... Read More
MASON, Ohio / Feb 21, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2022 and full year 2022 financial results. “We delivered another outstanding year of growth in 2022, as we expanded adoption across our broad portfolio of... Read More
MASON, Ohio / Feb 17, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33 rd Annual Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, March 15, 2023 at 8:00... Read More
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio / Jan 31, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that... Read More
MASON, Ohio / Jan 24, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time... Read More
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance. Preliminary, unaudited revenue for fourth quarter 2022 is expected to be approximately $88.0 million,... Read More
Recursion

COPYRIGHT ©2023 HEALTH STOCKS HUB